Literature DB >> 33335078

Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer.

Javier A Menendez1,2, Susan K Peirce3, Adriana Papadimitropoulou4, Elisabet Cuyàs1,2, Travis Vander Steen5, Sara Verdura1,2, Luciano Vellon6, Wen Y Chen7, Ruth Lupu5,8,9.   

Abstract

Progesterone receptor (PR) isoforms can drive unique phenotypes in luminal breast cancer (BC). Here, we hypothesized that PR-B and PR-A isoforms differentially modify the cross-talk between prolactin and fatty acid synthase (FASN) in BC. We profiled the responsiveness of the FASN gene promoter to prolactin in T47Dco BC cells constitutively expressing PR-A and PR-B, in the PR-null variant T47D-Y cell line, and in PR-null T47D-Y cells engineered to stably re-express PR-A (T47D-YA) or PR-B (T47D-YB). The capacity of prolactin to up-regulate FASN gene promoter activity in T47Dco cells was lost in T47D-Y and TD47-YA cells. Constitutively up-regulated FASN gene expression in T47-YB cells and its further stimulation by prolactin were both suppressed by the prolactin receptor antagonist hPRL-G129R. The ability of the FASN inhibitor C75 to decrease prolactin secretion was more conspicuous in T47-YB cells. In T47D-Y cells, which secreted notably less prolactin and downregulated prolactin receptor expression relative to T47Dco cells, FASN blockade resulted in an augmented secretion of prolactin and up-regulation of prolactin receptor expression. Our data reveal unforeseen PR-B isoform-specific regulatory actions in the cross-talk between prolactin and FASN signaling in BC. These findings might provide new PR-B/FASN-centered predictive and therapeutic modalities in luminal intrinsic BC subtypes.

Entities:  

Keywords:  G129R; endocrine therapy; luminal breast cancer; prolactin receptor

Mesh:

Substances:

Year:  2020        PMID: 33335078      PMCID: PMC7803566          DOI: 10.18632/aging.202289

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  131 in total

1.  Progesterone induces expression of the prolactin receptor gene through cooperative action of Sp1 and C/EBP.

Authors:  Anita S Goldhar; Renqin Duan; Erika Ginsburg; Barbara K Vonderhaar
Journal:  Mol Cell Endocrinol       Date:  2011-01-14       Impact factor: 4.102

2.  Prolactin modulates TRPV1 in female rat trigeminal sensory neurons.

Authors:  Anibal Diogenes; Amol M Patwardhan; Nathaniel A Jeske; Nikita B Ruparel; Vincent Goffin; Armen N Akopian; Kenneth M Hargreaves
Journal:  J Neurosci       Date:  2006-08-02       Impact factor: 6.167

3.  Differential pharmacologic properties of the two C75 enantiomers: (+)-C75 is a strong anorectic drug; (-)-C75 has antitumor activity.

Authors:  Kamil Makowski; Paula Mera; David Paredes; Laura Herrero; Xavier Ariza; Guillermina Asins; Fausto G Hegardt; Jordi García; Dolors Serra
Journal:  Chirality       Date:  2013-05       Impact factor: 2.437

4.  Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness.

Authors:  Paola A Rojas; María May; Gonzalo R Sequeira; Andrés Elia; Michelle Alvarez; Paula Martínez; Pedro Gonzalez; Stephen Hewitt; Xiaping He; Charles M Perou; Alfredo Molinolo; Luz Gibbons; Martin C Abba; Hugo Gass; Claudia Lanari
Journal:  J Natl Cancer Inst       Date:  2017-07-01       Impact factor: 13.506

5.  Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells.

Authors:  E M McGowan; C L Clarke
Journal:  Mol Endocrinol       Date:  1999-10

6.  Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming.

Authors:  Caroline H Diep; Todd P Knutson; Carol A Lange
Journal:  Mol Cancer Res       Date:  2015-11-17       Impact factor: 5.852

7.  Tyrosine phosphorylation of Grb2: role in prolactin/epidermal growth factor cross talk in mammary epithelial cell growth and differentiation.

Authors:  Eric Haines; Parham Minoo; Zhenqian Feng; Nazila Resalatpanah; Xin-Min Nie; Manuela Campiglio; Laura Alvarez; Eftihia Cocolakis; Mohammed Ridha; Mauricio Di Fulvio; Julian Gomez-Cambronero; Jean-Jacques Lebrun; Suhad Ali
Journal:  Mol Cell Biol       Date:  2009-03-09       Impact factor: 4.272

8.  Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.

Authors:  Javier A Menendez; Inderjit Mehmi; Vishal A Verma; Poh K Teng; Ruth Lupu
Journal:  Mol Carcinog       Date:  2004-11       Impact factor: 4.784

9.  Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform.

Authors:  Biserka Mulac-Jericevic; John P Lydon; Francesco J DeMayo; Orla M Conneely
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-01       Impact factor: 11.205

Review 10.  Molecular determinants of context-dependent progesterone receptor action in breast cancer.

Authors:  Christy R Hagan; Carol A Lange
Journal:  BMC Med       Date:  2014-02-20       Impact factor: 8.775

View more
  2 in total

1.  Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells.

Authors:  Barbara Schroeder; Travis Vander Steen; Ingrid Espinoza; Chandra M Kurapaty Venkatapoorna; Zeng Hu; Fernando Martín Silva; Kevin Regan; Elisabet Cuyàs; X Wei Meng; Sara Verdura; Aina Arbusà; Paula A Schneider; Karen S Flatten; George Kemble; Joan Montero; Scott H Kaufmann; Javier A Menendez; Ruth Lupu
Journal:  Cell Death Dis       Date:  2021-10-21       Impact factor: 8.469

2.  Landscape of the oncogenic role of fatty acid synthase in human tumors.

Authors:  Xulei Huo; Lairong Song; Da Li; Ke Wang; Yali Wang; Feng Chen; Liwei Zhang; Liang Wang; Junting Zhang; Zhen Wu
Journal:  Aging (Albany NY)       Date:  2021-12-08       Impact factor: 5.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.